Drug Trial Radar · NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
May 31, 2027
Study completion Jun 3, 2027
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
Specified dose on specified days
MezigdomideDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
- Number of participants with Serious AEsTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
- Number of participants with AEs meeting protocol-defined DLT criteriaTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
- Number of participants with AEs leading to discontinuationTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
- Number of deathsTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
- Recommended Phase 2 Dose (RP2D)Time frame: From first participant enrollment until the last participant is no longer evaluable for response or has progressed or the last survival follow-up (At approximately 5 years)
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Yale New Haven Hospital-Smilow Cancer Center
New Haven, Connecticut · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Local Institution - 0026
Vancouver, British Columbia, Canada · Not yet recruiting
QEII Health Sciences Centre - Victoria General Site
Halifax, Nova Scotia, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Local Institution - 0030
Suzhou, Jiangsu, China · Not yet recruiting
Tongji University - Shanghai Fourth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Universitaetsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Evangelismos General Hospital of Athens
Athens, Attikí, Greece · Recruiting
Alexandra General Hospital of Athens
Athens, Attikí, Greece · Recruiting
Sykehusapoteket Ull
Oslo, Norway · Recruiting
St. Olavs Hospital
Trondheim, Sør-Trøndelag, Norway · Recruiting
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, Spain · Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
University College London Hospital
London, England, United Kingdom · Recruiting
Royal Marsden Hospital (Sutton)
London, Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.